A carregar...

Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial

BACKGROUND: Guidelines recommend reducing elevated serum phosphate in patients with CKD. Tenapanor, a minimally absorbed inhibitor of gastrointestinal sodium/hydrogen exchanger 3 (NHE3), reduces paracellular phosphate transport. METHODS: In this phase 3 randomized, double-blind trial, we randomly as...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Soc Nephrol
Main Authors: Block, Geoffrey A., Rosenbaum, David P., Yan, Andrew, Chertow, Glenn M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Nephrology 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6442342/
https://ncbi.nlm.nih.gov/pubmed/30846557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2018080832
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!